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WPRT with intensity modulation techniques and long-term 
androgen-deprivation therapy. Strict radiotherapy dose-
volume constraints were used for treatment planning to 
minimize the risk of serious toxicity. 
PRO data (UCLA-Prostate Cancer Index scale) was available 
for 450 patients. Patients with less than 2 year follow-up 
data and any patients without acute (10 week after RT 
initiation) data were excluded, giving 251 patients for 
analysis. Median follow-up was 5 years. Only bowel habit 
outcomes were included for this analysis (questions 17 to 21). 
Data from patients with positive toxicity scores at baseline 
was excluded on an endpoint-by-endpoint basis.  
We separated patients according to acute toxicity into two 
groups using question-specific toxicity grade cut-offs which 
differed between each PRO question. We then assessed if the 
group with acute toxicity had more toxicity in the late setting 
by calculating the odds-ratios (OR); we also computed p-
values using Fisher’s exact test. seline was excluded on an 
endpoint-by-endpoint basis.  
 
Results: We found that patients with positive self-reported 
acute GI toxicity at 10 weeks have an increased risk of 
developing serious late GI problems, while patients without 
toxicity are more likely to be free of chronic toxicity (table 
1). as excluded on an endpoint-by-endpoint basis.  
 
 
 
Conclusion: Patients with moderate to severe acute bowel 
toxicity are at increased risk of serious late GI problems 
which impact quality of life, potentially reflecting a 
consequential late effect. Tailoring treatment with the 
modification of treatment planning according to early clinical 
outcomes may prove to be necessary to tackle this problem. 
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Purpose or Objective: Evaluate the utility of SBRT in terms 
of local control (LC), global survival (OS), compliance to the 
treatment and toxicity in patient with oligometastatic and 
hormone refractary prostate cancer, limited to the skeletal 
structures. 
 
Material and Methods: 46 patients with bone metastases 
from prostate cancer, were treated with SBRT between 
January 2009 and August 2015. At diagnosis 15/46 patients 
presented bone metastases. Bone lesions irradiate were 131 
(range 1-4). Median age was 68 years (range 54-85). Median 
PSA pre-treatment was 168,1 ng/ml (range 0,23 -1.470). 
Patients received a median dose of 30 Gy (range 8-40 Giy) in 
3 fractions (range 1 -5). The treatment was delivery by LINAC 
6 MeV (Elekta Synergy-S) using technical IGRT-VMAT. All 
patients received some form of androgen-deprivation therapy 
(ADT) after completing SBRT. 18/46 patients was submitted 
systemic chemotherapy treatment. 
 
Results: Median follow-up was 22 months (range 1-78). LC 
was 100% and OS 50,2% at 5 years. 22/46 patients were died 
for progression disease, 24/46 patient were still alive, of 
these 14 were disease free and 10 were in progressione 
disease. The first post-SBRT PSA was lower than pre-
treatment levels in 30 patients (65,2%) and continued to 
decline or remain undetectable in 23 patients (50%) at 
follow-up of 6 months. Median PSA post-treatment was 32,4 
(range 0,29-196). No severe acute or late toxicity of grade >2 
was observed. 
 
Conclusion: SBRT is a safe and effective treatment for 
prostate cancer metastases, presenting excellent LC and an 
acceptable toxicity profile in selected patient with hormone 
refractary disease. More importantly, half the patient 
achieving reductions in serum PSA values. 
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Purpose or Objective: Primary focal therapy has been 
explored for 20 years now, and more than 2000 patients have 
been treated so far with several techniques but only limited 
data have been published on the primary focal radiotherapy 
(FRT). From the technical point of view, primary FRT can be 
performed through either focal brachytherapy or external 
beam radiotherapy. The majority of series include both low-
dose-rate (LDR) and high-dose-rate (HDR) brachytherapy, and 
only recently the feasibility of primary FRT by external beam 
irradiation has been reported. The current review aims to 
assess the available evidence for primary FRT performed 
either by the means of brachytherapy or external beam 
radiotherapy.  
 
Material and Methods: Inclusion criteria were: Medline 
search for full paper in English language on primary FRT for 
early prostate cancer including review articles, planning 
studies or patient series (clinical outcome available) 
published before May 31, 2015.  
 
Results: Twenty-two papers have been found: 11 review 
articles, 4 planning studies and 7 patient series. Eleven 
review articles were dedicated to all types of focal therapy 
including FRT and 2 to FRT only. All planning studies were 
performed on cohort of 5-10 patients and included 
brachytherapy both HDR (24 patients overall), and LDR (9 
patients). All studies underline the significant organs-at-risk 
dose reduction as well as the higher sensitivity to systematic 
set-up error as target volume decreases from whole-gland to 
hemi-gland and to ultra-focal target. Patient series included 
together 715 patients (range 8-318, 99% treated with 
brachytherapy). Median follow-up period was 33.6 months 
(range 2-61 months). Promising tumour control was 
highlighted in low-risk cancer. In intermediate-risk tumours, 
FRT might be suboptimal (see Table 1). Moreover, some 
reports on consensus criteria are already available in 
literature. 
 
